Omeros Long Term Debt 2012-2026 | OMER

Omeros long term debt from 2012 to 2026. Long term debt can be defined as the sum of all long term debt fields.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Omeros Annual Long Term Debt
(Millions of US $)
2025 $209
2024 $167
2023 $213
2022 $221
2021 $313
2020 $236
2019 $158
2018 $149
2017 $83
2016 $80
2015 $50
2014 $26
2013 $15
2012 $20
2011 $14
Omeros Quarterly Long Term Debt
(Millions of US $)
2026-06-30 $97
2026-03-31 $137
2025-12-31 $209
2025-09-30 $160
2025-06-30 $151
2025-03-31 $159
2024-12-31 $167
2024-09-30 $189
2024-06-30 $191
2024-03-31 $213
2023-12-31 $213
2023-09-30 $222
2023-06-30 $222
2023-03-31 $221
2022-12-31 $221
2022-09-30 $315
2022-06-30 $314
2022-03-31 $314
2021-12-31 $313
2021-09-30 $313
2021-06-30 $313
2021-03-31 $312
2020-12-31 $236
2020-09-30 $233
2020-06-30 $163
2020-03-31 $161
2019-12-31 $158
2019-09-30 $156
2019-06-30 $153
2019-03-31 $151
2018-12-31 $149
2018-09-30 $132
2018-06-30 $130
2018-03-31 $85
2017-12-31 $83
2017-09-30 $83
2017-06-30 $82
2017-03-31 $81
2016-12-31 $80
2016-09-30 $70
2016-06-30 $70
2016-03-31 $50
2015-12-31 $50
2015-09-30 $19
2015-06-30 $21
2015-03-31 $24
2014-12-31 $26
2014-09-30 $29
2014-06-30 $31
2014-03-31 $32
2013-12-31 $15
2013-09-30 $16
2013-06-30 $18
2013-03-31 $19
2012-12-31 $20
2012-09-30 $9
2012-06-30 $10
2012-03-31 $12
2011-12-31 $14
2011-09-30 $15
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.264B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $178.385B 19.60
Medtronic (MDT) Ireland $119.983B 16.40
Stryker (SYK) United States $108.118B 20.21
EssilorLuxottica (ESLOY) France $79.433B 0.00
Boston Scientific (BSX) United States $65.288B 14.03
Lonza Group Ag (LZAGY) Switzerland $45.930B 0.00
Medline (MDLN) United States $42.846B 0.00
Agilent Technologies (A) United States $41.387B 24.22
ResMed (RMD) United States $32.167B 19.96
GE HealthCare Technologies (GEHC) United States $29.021B 13.88
Koninklijke Philips (PHG) Netherlands $24.651B 13.13
Terumo (TRUMY) Japan $21.625B 20.65
Zimmer Biomet Holdings (ZBH) United States $18.414B 11.38
Baxter (BAX) United States $12.336B 11.64
Smith & Nephew SNATS (SNN) United Kingdom $11.926B 0.00
Bio-Rad Laboratories (BIO) United States $9.854B 39.71
Demant (WILYY) Denmark $9.592B 0.00
Insulet (PODD) United States $9.557B 23.48
Sunny Optical Technology (SNPTF) China $9.142B 0.00
Lantheus Holdings (LNTH) United States $6.548B 20.15
Raia Drogasil SA - (RADLY) $4.931B 0.00
Haemonetics (HAE) United States $4.837B 21.22
BillionToOne (BLLN) United States $4.757B 144.03
DiaSorin S.p.A (DSRLF) Italy $4.705B 0.00
Envista Holdings (NVST) United States $4.142B 17.54
ICU Medical (ICUI) United States $3.939B 23.52
AtriCure (ATRC) United States $2.838B 242.57
Neogen (NEOG) United States $2.606B 45.96
Curaleaf Holdings (CURLD) Canada $2.388B 0.00
Curaleaf Holdings (CURLF) United States $2.356B 0.00
Prestige Consumer Healthcare (PBH) United States $2.256B 10.77
Trulieve Cannabis (TRLV) United States $2.238B 0.00
GN Store Nord (GNNDY) Denmark $2.207B 0.00
Perrigo (PRGO) Ireland $1.894B 5.46
LeMaitre Vascular (LMAT) United States $1.847B 29.69
Shandong Weigao Medical Polymer (SHWGF) China $1.798B 0.00
Maravai LifeSciences Holdings (MRVI) United States $1.736B 0.00
BioLife Solutions (BLFS) United States $1.733B 221.44
Phibro Animal Health (PAHC) United States $1.459B 11.20
Green Thumb Industries (GTBIF) United States $1.428B 15.23
Kestra Medical Technologies (KMTS) United States $1.410B 0.00
Lumexa Imaging Holdings (LMRI) United States $1.094B 0.00
CeriBell (CBLL) United States $0.934B 0.00
InMode (INMD) Israel $0.856B 11.91
AdaptHealth (AHCO) United States $0.802B 16.80
VAREX IMAGING (VREX) United States $0.777B 17.09
QuidelOrtho (QDEL) United States $0.763B 8.24
Glass House Brands (GLAS) United States $0.760B 0.00
Valneva SE (VALN) France $0.633B 0.00
Vireo Growth (VREOF) United States $0.582B 0.00
Tilray Brands (TLRY) Canada $0.564B 0.00
Brainsway (BWAY) Israel $0.548B 30.98
Evolus (EOLS) United States $0.524B 0.00
Cerus (CERS) United States $0.514B 0.00
Capricor Therapeutics (CAPR) United States $0.512B 0.00
Vireo Growth (VREOD) United States $0.451B 0.00
Verano Holdings (VRNO) United States $0.438B 0.00
Verano Holdings (VRNOD) United States $0.425B 0.00
Canopy Growth (CGC) Canada $0.422B 0.00
SEMPERIT AG HLD (SEIGY) Austria $0.395B 8.28
Cresco Labs (CRLBF) United States $0.373B 0.00
SNDL (SNDL) Canada $0.353B 0.00
Village Farms (VFF) Canada $0.347B 15.78
Viemed Healthcare (VMD) United States $0.337B 24.56
Sanara MedTech (SMTI) United States $0.321B 159.00
TriSalus Life Sciences (TLSI) United States $0.294B 0.00
MacroGenics (MGNX) United States $0.268B 0.00
Aurora Cannabis (ACB) Canada $0.247B 13.14
High Tide (HITI) Canada $0.234B 52.60
OraSure Technologies (OSUR) United States $0.232B 0.00
Utah Medical Products (UTMD) United States $0.225B 21.55
Owens & Minor (OMI) United States $0.217B 2.17
TerrAscend (TSNDF) Canada $0.205B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.194B 0.00
Exagen (XGN) United States $0.178B 0.00
Quipt Home Medical (QIPT) United States $0.157B 0.00
Jin Medical (ZJYL) China $0.155B 0.00
Organigram Global (OGI) Canada $0.152B 0.00
Apyx Medical (APYX) United States $0.127B 0.00
Quanterix (QTRX) United States $0.118B 0.00
Fonar (FONR) United States $0.115B 16.53
ImmuCell (ICCC) United States $0.088B 121.38
Accendra Health (ACH) United States $0.086B 4.87
FitLife Brands (FTLF) United States $0.086B 11.30
Jushi Holdings (JUSHF) United States $0.083B 0.00
Sharps Technology (STSS) United States $0.065B 0.00
InterCure (INCR) Israel $0.058B 0.00
Hongchang (HCIL) China $0.052B 0.00
Biote (BTMD) United States $0.050B 4.12
Nephros (NEPH) United States $0.048B 40.27
Veru (VERU) United States $0.040B 0.00
Sanuwave Health (SNWV) United States $0.037B 17.71
United-Guardian (UG) United States $0.033B 13.26
Rockwell Medical (RMTI) United States $0.031B 0.00
Cellectar Biosciences (CLRB) United States $0.022B 0.00
Modular Medical (MODD) United States $0.021B 0.00
Cytosorbents (CTSO) United States $0.019B 0.00
Bonk (BNKK) United States $0.011B 0.00
Flora Growth (FLGC) United States $0.009B 0.00
Innovative Eyewear (LUCY) United States $0.007B 0.00
Trinity Biotech (TRIB) Ireland $0.006B 0.00
Zynex (ZYXI) United States $0.004B 0.00
Meihua Medical Technologies (MHUA) China $0.002B 0.00
Agape ATP (ATPC) $0.002B 0.00
GlucoTrack (GCTK) United States $0.002B 0.00
Akanda (AKAN) Canada $0.002B 0.00
IM Cannabis (IMCC) Canada $0.000B 0.00
INLIF (INLF) China $0.000B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.000B 0.00